Table 2.
Progression-free survival (PFS) and overall survival (OS) by codon location of the KRAS mutation.
| Point survival (95% CI), months | ||||||||
|---|---|---|---|---|---|---|---|---|
| All patients with a KRAS mutation (n = 337) | G12A (n = 114) | G12C (n = 20) | G12D (n = 72) | G12R (n = 6) | G12S (n = 16) | G12V (n =72) | G13D (n = 37) | |
| PFS | ||||||||
| Median | 10.4 (9.3-11.6) | 9.7 (8.1-11.3) | 7.1 (2.5-11.8) | 10.0 (8.0-11.9) | 7.8 (0.0-20.2) | 8.4 (0.0-20.2) | 12.4 (11.2-13.6) | 11.7 (6.9-16.5) |
| Mean | 16.6 (14.3-18.8) | 15.3 (11.9-18.7) | 16.9 (7.7-26.2) | 13.7 (10.7-16.7) | 13.2 (5.5-20.9) | 16.3 (5.3-27.3) | 18.9 (14.5-23.2) | 12.8 (9.7-15.8) |
| OS | ||||||||
| Median | 25.4 (22.8-28.0) | 26.8 (21.9-31.6) | 31.1 (21.4-40.8) | 23.4 (19.1-27.8) | 14.5 (0.0-39.0) | 10.3 (2.5-18.0) | 28.5 (22.5-34.5) | 19.1 (13.0-25.2) |
| Mean | 31.8 (29.0-34.7) | 30.8 (26.7-34.9) | 39.1 (28.7-49.5) | 30.5 (24.8-36.3) | 27.9 (10.0-45.8) | 23.7 (9.4-38.0) | 34.9 (29.5-40.3) | 23.6 (18.3-28.9) |
| Patients who underwent surgery | ||||||||
| Median | 46.5 (39.0-54.0) | 47.5 (37.7-57.4) | — | 37.9 (19.9-56.0) | — | 25.8 (15.7-35.9) | — | 33.3 (15.1-51.5) |
| Mean | 50.2 (44.2-56.1) | 52.4 (43.1-61.8) | 65.6 (63.7-67.6) | 44.8 (32.6-57.1) | 47.1 (47.1-47.1) | 31.3 (19.2-43.5) | 54.4 (43.7-65.1) | 34.6 (22.7-46.5) |
| Patients who did not undergo surgery | ||||||||
| Median | 20.0 (17.1-22.8) | 20.9 (17.1-24.7) | 25.8 (15.9-35.6) | 20.6 (15.2-25.9) | 6.2 (4.8-7.7) | 8.00 (4.9-11.1) | 22.6 (14.4-30.9) | 17.0 (13.2-20.9) |
| Mean | 24.2 (21.8-26.6) | 23.7 (20.5-26.8) | 27.0 (17.5-36.4) | 23.0 (18.8-27.2) | 8.7 (3.0-14.4) | 16.2 (0.9-31.5) | 28.7 (23.4-34.0) | 19.4 (14.5-24.3) |
| P valuea | <.001 | <.001 | .003 | .002 | .025 | .062 | <.001 | .013 |
aLog rank test comparing median OS for surgery vs no surgery subgroups within each codon mutation group (significant values are shown in bold).
—Due to the low number of patients having an event in the group it was not possible to calculate a median value.
Abbreviation: KRAS, Kirsten rat sarcoma viral oncogene homolog.